fbpx

Advanced Viscosupplementation in Osteoarthritis: The Promise of Arthrosamid

Advanced Viscosupplementation in Osteoarthritis: The Promise of Arthrosamid

Introduction to Advanced Viscosupplementation

Osteoarthritis (OA) is a widespread, chronic joint condition that gradually erodes cartilage, leading to pain, stiffness, and a reduced quality of life. Affecting millions globally, OA poses a significant challenge for both individuals and healthcare systems. One common treatment option is viscosupplementation , where hyaluronic acid (HA) is injected directly into the joint to temporarily improve lubrication and ease symptoms.

This approach works by supplementing the natural synovial fluid , which cushions and lubricates the joint. While HA injections can reduce pain and improve mobility, their effects are often short-lived, which means patients may require repeated injections.

Arthrosamid represents a new generation of viscosupplementation that seeks to provide longer-lasting joint support. Unlike traditional HA, Arthrosamid offers more than just temporary relief—it aims to deliver sustained cushioning with a single treatment.

In this article, we’ll explore how Arthrosamid differs from conventional HA injections, review the key clinical evidence, and discuss the latest advances in OA management that offer hope for those seeking longer-term comfort and better joint health.

How Do Hyaluronic Acid and Arthrosamid Work?

Hyaluronic acid is a naturally occurring molecule found in healthy joint fluid, acting as both a lubricant and shock absorber. In people with osteoarthritis , this fluid becomes thinner and less effective, contributing to joint discomfort. Injecting supplemental HA is designed to restore some of the joint’s natural slipperiness, reducing pain and allowing for easier movement—at least temporarily.

Although HA is generally safe and well-tolerated, its benefits usually last only a few months, as the substance breaks down quickly within the joint from enzymes and normal activity. Whether low or high molecular weight, most HA products require multiple injections over time to sustain relief.

Arthrosamid takes a different approach. Rather than simply topping up joint fluid, it uses a medical-grade polyacrylamide hydrogel . This soft, cushioning gel forms a mesh-like structure inside the joint, providing mechanical support and resisting breakdown much more effectively than HA. Because it remains in the joint for an extended period, Arthrosamid can offer pain relief and improved function that lasts well beyond traditional HA injections—all from a single treatment.

What Does the Clinical Evidence Say?

When choosing the best treatment, it’s crucial to look at what the studies show. Several trials have compared Arthrosamid to traditional HA injections and corticosteroids in patients with knee osteoarthritis .

In one retrospective analysis of 150 patients, all groups— Arthrosamid , HA, and corticosteroid—experienced pain relief within three months. At six and twelve months, those treated with Arthrosamid maintained greater pain relief and better joint function compared to those who received corticosteroids. Arthrosamid also showed sustained benefits compared to HA, with longer-lasting symptom improvement. Importantly, both treatments were found to be safe and well tolerated.

A larger randomized controlled trial with 239 participants confirmed these findings. Arthrosamid was at least as effective as HA at reducing pain and improving function over 26 weeks. Some groups, such as younger patients, those with a healthy body mass index, or those with moderate OA severity, experienced even more pronounced benefits a year after injection. This suggests that tailoring treatment to individual patient profiles may yield the best results.

Further cohort studies have shown that polyacrylamide hydrogel can provide lasting relief for up to two years in some patients, especially those who are older, have less severe OA, and have bilateral knee involvement. These studies also confirm a strong safety profile—it’s generally well-tolerated, with minimal side effects such as temporary discomfort at the injection site.

While these results are promising, it’s important to remember that individual responses can vary. More research will help determine which patients benefit most and how this treatment fits into long-term OA care.

The Importance of Expert Care: Professor Paul Lee and MSK Doctors

Getting the most from viscosupplementation depends not just on the product, but on professional expertise. Professor Paul Lee and his team at MSK Doctors are dedicated to providing comprehensive, patient-centred musculoskeletal care.

At MSK Doctors, each patient undergoes a thorough evaluation to identify the most suitable treatment plan—considering factors like joint damage severity and overall health. Treatment is personalised, with close follow-up and a focus on optimising long-term joint function rather than offering just temporary relief.

This tailored approach supports not only immediate pain reduction but also sustained improvement in joint health. By combining advanced therapies like Arthrosamid with clinical expertise, MSK Doctors help patients manage osteoarthritis more effectively, improving overall quality of life.

Looking Ahead: What’s Next for Arthrosamid and OA Treatment?

Research in osteoarthritis is advancing rapidly, with new treatment combinations being explored. Scientists are looking at how viscosupplementation can be paired with regenerative medicine , physical therapy , and novel drugs to further improve outcomes. There’s also growing interest in using biological markers to personalise when and how different treatments are administered.

Selecting the right patients for Arthrosamid is essential. Age, body weight, OA severity, and overall health can influence results, so careful assessment and monitoring are key. Clinicians increasingly use validated tools, like the Visual Analog Scale (VAS) for pain and WOMAC for function, to track patient progress and guide treatment.

The future of OA care lies in developing personalised treatment pathways—ensuring patients receive interventions that offer the greatest benefit, with the fewest side effects, at the right time in their disease journey.

Conclusion: Balanced Expectations and Informed Choices

Arthrosamid holds real promise for delivering longer-lasting relief than traditional hyaluronic acid injections , especially for select patients. By resisting breakdown inside the joint, this innovative gel can help prolong comfort and preserve function.

However, no single treatment is right for everyone. Partnering with experienced healthcare professionals—like the team at MSK Doctors—ensures treatment choices are tailored to each person’s needs and expectations. As always, patients should seek personalised advice from their healthcare provider before deciding on any course of treatment.


For individual medical advice, please consult a qualified healthcare professional.

References

  • Gao, H. C. K., Akhtar, M., Creedon, C., Nar, Ö. O., Verma, T., & Lee, P. Y. F. (2025). Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. Journal of Clinical Orthopaedics and Trauma. https://doi.org/10.1016/j.jcot.2025.103136
  • Strauss, E. J., Hart, J., Miller, M. D., Altman, R. D., & Rosen, J. (2009). Hyaluronic acid viscosupplementation and osteoarthritis. The American Journal of Sports Medicine, 37(8), 1636-1644. https://doi.org/10.1177/0363546508326984
  • Abate, M., Pelotti, P., De Amicis, D., Di Iorio, A., Galletti, S., & Salini, V. (2008). Viscosupplementation with hyaluronic acid in hip osteoarthritis (a review). Upsala Journal of Medical Sciences, 113(3), 261-278. https://doi.org/10.3109/2000-1967-233

Frequently Asked Questions

Arthrosamid uses a medical-grade polyacrylamide hydrogel, which provides longer-lasting cushioning inside the joint, whereas traditional hyaluronic acid injections offer only temporary symptom relief. This innovative approach helps maintain joint support for a more extended period between treatments.

MSK Doctors offer personalised, comprehensive musculoskeletal care led by Professor Paul Lee. They thoroughly evaluate each patient’s needs and use advanced therapies, like Arthrosamid, to optimise joint function and long-term health, instead of just focusing on short-term symptom relief.

Professor Paul Lee is highly regarded for his expertise in musculoskeletal medicine and advanced therapies. He leads the MSK Doctors team, ensuring evidence-based, patient-centric care when administering cutting-edge treatments such as Arthrosamid, tailored to the unique needs of each individual.

Clinical studies have demonstrated that Arthrosamid is safe and generally well tolerated, offering sustained pain relief and improved function in patients with knee osteoarthritis. Research shows it can outperform traditional treatments in certain patient groups, providing longer-lasting benefits for many individuals.

At MSK Doctors, each treatment plan is tailored using careful assessments of joint condition, patient health, and individual goals. This approach, combined with advanced therapies and ongoing follow-up, ensures patients receive the most suitable care for their specific osteoarthritis needs.

Copyright Content © 2025 Lincolnshire Hip Clinic